Lorem Vascular
Lorem Vascular is a Singapore-based medical device distributor that exclusively commercializes Cytori Therapeutics' Celution System® across Asia-Pacific, selling a point-of-care cell separation platform to hospitals and clinics for regenerative medicine applications.
- Company typePrivate
- Founded-
- HeadquartersSingapore, Singapore
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lorem Vascular does
Lorem Vascular is a Singapore-headquartered medical device distributor that holds exclusive Asia-Pacific commercialization rights (Australia, Singapore, Malaysia, Hong Kong, China) to Cytori Therapeutics' Celution System®, a closed and sterile point-of-care cell separation system that isolates stromal vascular fraction (SVF) / adipose-derived regenerative cells (ADRC) from lipoaspirates. The company targets healthcare providers and medical facilities — including hospitals, clinics, and specialists in plastic surgery, wound care, urology, rheumatology, orthopedics, and sports medicine — for applications spanning breast reconstruction, chronic wounds (radiation- or diabetes-related), erectile dysfunction, systemic scleroderma, osteoarthritis, and sports injuries.
The Celution System® is positioned as the market-leading SVF/ADRC isolation platform, reportedly obtaining the highest mean number of viable nucleated cells among commercially available systems, with a peer-reviewed head-to-head comparison (Aronowitz & Ellenhorn, Plast Reconstr Surg, 2013) cited as supporting evidence. The underlying technology is licensed inbound from Cytori Therapeutics rather than internally developed; Lorem Vascular's value capture is in distribution, clinical onboarding, and regional commercialization rather than in IP origination.
Lorem Vascular operates with a small team (1-10 employees) across three regional offices: Singapore (headquarters at 16 Raffles Quay), Beijing (China Life Tower), and Kuala Lumpur (Mid Valley City). The go-to-market is enterprise field sales with an enquiry-based portal model; pricing is not publicly disclosed, and revenue mechanics rely on direct hardware sales of the Celution System® and consumables to healthcare providers. The company reports having served over 6,000 patients cumulatively worldwide, but no revenue, unit shipment, or growth figures are disclosed.
Lorem Vascular firmographics
Firmographics- Name
- Lorem Vascular
- Legal name
- Lorem Vascular
- Website
- https://loremvascular.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lorem Vascular is a Singapore-based medical device distributor that exclusively commercializes Cytori Therapeutics' Celution System® across Asia-Pacific, selling a point-of-care cell separation platform to hospitals and clinics for regenerative medicine applications.
- Ownership category
- akta.pro rank
Lorem Vascular industry classification
Industry- NAICS
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
- SIC
- Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Acellular/Decellularized Matrices & ECM Products (HLAAAGAF)
Keywords
Where Lorem Vascular is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices3 records
Markets served
Lorem Vascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Celution System® Product Distribution: Distribution and sale of the Celution System® - a medical device for regenerative medicine procedures. The company commercializes Cytori Therapeutics' flagship technology in the Asia-Pacific region (Australia, Singapore, Malaysia, Hong Kong, and China) for applications in breast reconstruction, chronic wounds, erectile dysfunction, systemic scleroderma, osteoarthritis, and sports injuries.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Lorem Vascular product offering
Product offeringCore offering
Lorem Vascular distributes the Celution System®, a closed, sterile, point-of-care cell separation medical device used to process adipose tissue and extract regenerative cell populations for autologous therapies. The company holds exclusive Asia-Pacific distribution rights for the device, which has been used to treat 6,000+ patients worldwide and is cleared for cell-assisted lipotransfer, wound healing, and urinary/stress incontinence indications.
Product overview
Lorem Vascular offers a single flagship product, the Celution System®, developed by Cytori Therapeutics, Inc. (U.S.A.). This closed and sterile cell separation system isolates stromal vascular fraction (SVF)/adipose derived regenerative cells (ADRC) from lipoaspirates at the point of care for regenerative medicine applications including breast reconstruction, chronic wounds, erectile dysfunction, systemic scleroderma, osteoarthritis, and sports injuries.
Differentiator
Problem solved
Functional benefit
Brands
- Celution System®: Market-leading closed and sterile cell separation system that isolates the stromal vascular fraction (SVF), also known as adipose derived regenerative cells (ADRC), from lipoaspirates at point of care. It obtains the highest mean number of viable nucleated cells among commercially available systems.
Quantifiable outcome
- Successfully helped more than 6000 patients worldwide achieve a better quality of life
Companies that use Lorem Vascular
Customer profileSegments1 record
Ideal customer profiles1 record
Lorem Vascular technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Lorem Vascular partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cytori Therapeutics, Inc.coreLorem Vascular holds exclusive rights to commercialize the Celution System® in Australia, Singapore, Malaysia, Hong Kong, and China. Cytori Therapeutics developed and manufactures the market-leading Celution System®, a closed and sterile cell separation system that isolates stromal vascular fraction (SVF)/adipose derived regenerative cells (ADRC) from lipoaspirates at point of care. This partnership enables Lorem Vascular to serve the regenerative medicine market across the Asia-Pacific region.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
Lorem Vascular competitors and assessment
Company assessmentDirect peers
- Tissue Genesis: Provider of adipose-derived cell isolation systems and regenerative-medicine therapies. Direct competitor in the SVF/ADRC isolation device category.
- InGeneron: Develops point-of-care adipose-derived regenerative cell isolation systems that directly compete with the Celution System® across the same autologous SVF/ADRC use cases Lorem Vascular serves.
- Cytori Therapeutics: Developer and licensor of the Celution System® that Lorem Vascular commercializes in APAC. Most direct peer given the shared product, technology, and customer base in cell-based regenerative medicine.
- Human Med: Manufacturer of cell-separation and lipotransfer systems used in regenerative and aesthetic medicine. Competes with the Celution System® on point-of-care cell preparation.
Broad incumbents
- Mesoblast: Larger regenerative-medicine company with a broader portfolio of cell-therapy products across cardiovascular, inflammatory, and orthopedic indications, overlapping with Lorem Vascular's disease targets.
Regional players
- DKSH Holding: Large APAC market-expansion services and healthcare distribution company covering many of the same geographies Lorem Vascular serves, providing a comparable commercial model for medical-device entry into the region.
- Zuellig Pharma: Major APAC healthcare distributor offering commercial reach across Singapore, Malaysia, Hong Kong, and other Lorem Vascular territories, with comparable medical-product distribution capabilities.
Emerging players
- BioRestorative Therapies: Developer of cell-based therapies using autologous adipose-derived stem cells, a directly comparable therapeutic modality to SVF/ADRC-based treatments delivered via the Celution System®.
- Pluristem Therapeutics: Clinical-stage cell-therapy company developing placenta-derived cell therapies for ischemic and inflammatory conditions, addressing some of the same regenerative-medicine indications Lorem Vascular serves.
- Caladrius Biosciences: Cell-therapy developer with programs in cardiovascular and autoimmune indications (e.g., scleroderma-relevant biology), operating in adjacent regenerative-medicicine territory to Lorem Vascular's Celution System use cases.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Lorem Vascular social profiles
Digital presenceLorem Vascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lorem Vascular leadership team
Management profileNumber of profiles
Profiles1 record
Lorem Vascular funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lorem Vascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lorem Vascular
What does Lorem Vascular do?
Lorem Vascular distributes the Celution System®, a closed, sterile, point-of-care cell separation medical device used to process adipose tissue and extract regenerative cell populations for autologous therapies. The company holds exclusive Asia-Pacific distribution rights for the device, which has been used to treat 6,000+ patients worldwide and is cleared for cell-assisted lipotransfer, wound healing, and urinary/stress incontinence indications.
Is Lorem Vascular a public or private company?
Lorem Vascular is a private company. It is currently operating.
When was Lorem Vascular founded?
Lorem Vascular was founded in -1. It employs 1 to 10 people.
Where is Lorem Vascular based?
Lorem Vascular is headquartered in Singapore, Singapore, in the Asia region.
How does Lorem Vascular make money?
One revenue line is on record: celution System® Product Distribution.
Who are Lorem Vascular's main competitors?
Direct peers on record are Tissue Genesis, InGeneron, Cytori Therapeutics and Human Med. Mesoblast is listed as a broad incumbent. Regional players are DKSH Holding and Zuellig Pharma. Emerging players are BioRestorative Therapies, Pluristem Therapeutics and Caladrius Biosciences.
Does Lorem Vascular have an API?
No public API is recorded for Lorem Vascular.
What industry is Lorem Vascular in?
Its primary akta.pro industry code is HLAAAGAF, Acellular/Decellularized Matrices & ECM Products. Its NAICS code is 423450 and its SIC code is 5047.